Estrogen, progesterone, and HER-2 receptor immunostaining in cytology: The effect of varied fixation on human breast cancer cells

Diagnostic Cytopathology

Volumn 41, Issue 10, 2013, Pages 864-870

  Maleki, Sara ^a   Dorokhova, Olena ^a   Sunkara, Jaya ^a   Schlesinger, Kathie ^a   Suhrland, Mark ^a   Oktay, Maja H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

breast cancer; cytology; fixation; hormone receptors; immunocytochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; FIXATIVE; FORMALDEHYDE; PARAFFIN; PROGESTERONE;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL STRAIN MCF 7; CENTROMERE; CONTROLLED STUDY; FALSE NEGATIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; PRECIPITATION; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; SCORING SYSTEM;

BREAST CANCER; CYTOLOGY; FIXATION; HORMONE RECEPTORS; IMMUNOCYTOCHEMISTRY;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; ESTROGENS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MCF-7 CELLS; PROGESTERONE; RECEPTOR, ERBB-2; TISSUE FIXATION;

EID: 84885021906     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.22973     Document Type: Article

References (18)

1. Payne SJ, Bowen RL, Jones JL, Wells CA,. Predictive markers in breast cancer-The present. Histopathology 2008; 52: 82-90.
2. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 966-978.
3. Morgan DA, Refalo NA, Cheung KL,. Strength of ER-positivity in relation to survival in ER-positive breast cancer treated by adjuvant tamoxifen as sole systemic therapy. Breast 2011; 20: 215-219.
4. Natali PG, Nicotra MR, Bigotti A, et al. Expression of the p185 encoded by HER-2 oncogene in normal and transformed human tissues. Int J Cancer 1990; 45: 457-461.
5. Stern DF, Heffernan PA, Weinberg RA,. p185, a product of the neu proto-oncogene, is a receptor like protein associated with tyrosine kinase activity. Mol Cell Biol 1986; 6: 1729-1740.
6. Ross JS, Fletcher JA,. The HER-2/neu oncogene: Prognostic factor, predictive factor and target for therapy. Semin Cancer Biol 1999; 9: 125-138.
7. Ross JS, Fletcher JA, Linette GP, et al. The Her-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy. Oncologist 2003; 8: 307-325.
8. Diaz NM,. Laboratory testing for HER-2/neu in breast carcinoma: An evolving strategy to predict response to targeted therapy. Cancer Control 2001; 8: 415-418.
9. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL,. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
10. Ross JS, Fletcher JA,. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 1999; 112 (Suppl 1): S53-S67.
11. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. American Society of Clinical Oncology; College of American Pathologists. J Clin Oncol 2007; 25: 118-145.
12. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 2010; 134: e48-e72. Review.
13. Fetsch PA, Abati A,. The effects of antibody clone and pretreatment method on the results of HER-2 immunostaining in cytologic samples of metastatic breast cancer: A query and a review of the literature. Diagn Cytopathol 2007; 35: 319-328.
14. Shabaik A, Lin G, Peterson M, Hasteh F, Tipps A, Datnow B, Weidner N,. Reliability of Her2/neu, estrogen receptor, and progesterone receptor testing by immunohistochemistry on cell block of FNA and serous effusions from patients withprimary and metastatic breast carcinoma. Diagn Cytopathol 2011; 39: 328-332. doi: 10.1002/dc.21389.
15. Hanley KZ, Birdsong GG, Cohen C, Siddiqui MT,. Immunohistochemical detection of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast carcinomas: Comparison on cell block, needle-core, and tissue block preparations. Cancer Cytopathol 2009; 117: 279-288.
16. Allred DC, Harvey JM, Berardo M, Clark GM,. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-168.
17. Paavilainen L, Edvinsson A, Asplund A, et al. The impact of tissue fixatives on morphology and antibody-based protein profiling in tissues and cells. J Histochem Cytochem 2010; 58: 237-246.
18. Moelans CB, ter Hoeve N, van Ginkel JW, ten Kate FJ, van Diest PJ,. Formaldehyde substitute fixatives. Analysis of macroscopy, morphologic analysis, and immunohistochemical analysis. Am J Clin Pathol 2011; 136: 548-556.